跳至主要内容
临床试验/NCT02033590
NCT02033590撤回不适用

Clinical and Economic Outcomes With the Use of SERI® Surgical Scaffold in Direct-to-implant Breast Reconstruction

Sofregen Medical, Inc.0 个研究点开始时间: 2014年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
发起方
主要终点
Incidence rate of implant loss (SERI® and breast implant)

研究概览

简要总结

The objective of this study is to prospectively observe clinical and economic outcomes with the use of SERI® in direct-to-implant breast reconstruction.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Be willing to undergo immediate breast reconstruction following a skin-sparing or nipple sparing mastectomy with healthy, sufficiently thick, well-vascularized skin flaps, and the implantation of SERI® Surgical Scaffold and breast implant
  • Be female, between 18 and 65 years of age at the time of enrollment

排除标准

  • Have undergone prior radiation treatment on the study breast(s) and/or is preoperatively evaluated to require radiation treatment to the study breast(s) during the course of the study
  • Have undergone a skin reducing mastectomy
  • Have a BMI that is <17 or ≥ 30
  • Predicted implant weight more than 500 grams
  • Have a known allergy to silk
  • Have an abscess or active infection at any location within one month prior to surgery
  • Be pregnant, lactating, or if of childbearing potential, be unwilling to use contraceptive methods and avoid pregnancy throughout the study

研究组 & 干预措施

SERI® Surgical Scaffold

Experimental

干预措施: Biodegradable (purified) surgical silk scaffold (Device)

结局指标

主要结局

Incidence rate of implant loss (SERI® and breast implant)

时间窗: 52 weeks

次要结局

未报告次要终点

研究者

发起方
Sofregen Medical, Inc.
申办方类型
Industry
责任方
Sponsor

相似试验